A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection
Status:
Completed
Trial end date:
1990-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the degree and sequence of immunologic enhancement and the cellular resistance to
certain infections after a single dose of atvogen (ampligen). In addition, the relationship
between activation of immune cells and biochemical markers of that activation will be
studied.
Treatment of patients with HIV infection must address both the primary viral infection and
the subsequent immune deficiency, which is the primary cause of mortality in AIDS. In vitro
studies of ampligen have shown it will inhibit HIV infection. Ampligen may also minimize the
toxicity of many drugs used in the treatment of AIDS and induce an antiviral state in the
brain that may be useful in treating neurologic symptoms of HIV infection. The time course
and degree of immunologic response to ampligen remain unknown although they are essential for
proper use of the drug in the treatment of HIV infection and perhaps other clinical problems.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)